Alumis Inc.

ALMS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023
Operating Activities
Net Income $-243.3M $-294.2M $-155.0M
Depreciation & Amortization $3.5M $3.2M $1.3M
Depreciation
Amortization
Stock-Based Compensation $43.5M $19.5M $8.6M
Net Cash from Operating Activities $-369.5M $-255.1M $-130.0M
Investing Activities
Capital Expenditures $653.0K $1.7M $4.5M
Business Acquisitions
Net Cash from Investing Activities $287.9M $-113.8M $60.5M
Financing Activities
Dividends Paid
Stock Repurchases $17.0K $6.0K $64.0K
Net Cash from Financing Activities $2.1M $492.4M $89.7M
Net Change in Cash
Free Cash Flow $-370.2M $-256.8M $-134.5M